tetano
Editor, Senior Moderator
Med Clin (Engl Ed)
. 2022 May 27;158(10):458-465.
doi: 10.1016/j.medcle.2021.05.022. Epub 2022 Jun 9.
Clinical features and prognosis of COVID-19 patients with metabolic syndrome: A multicenter, retrospective study
Jian Wang[SUP] 1 [/SUP], Li Zhu[SUP] 2 [/SUP], Longgen Liu[SUP] 3 [/SUP], Xuebing Yan[SUP] 4 [/SUP], Leyang Xue[SUP] 5 [/SUP], Songping Huang[SUP] 6 [/SUP], Biao Zhang[SUP] 7 [/SUP], Tianmin Xu[SUP] 3 [/SUP], Fang Ji[SUP] 4 [/SUP], Chunyang Li[SUP] 4 [/SUP], Fang Ming[SUP] 6 [/SUP], Yun Zhao[SUP] 8 [/SUP], Juan Cheng[SUP] 9 [/SUP], Kang Chen[SUP] 10 [/SUP], Xiang-An Zhao[SUP] 11 [/SUP], Dawen Sang[SUP] 9 [/SUP], Xinying Guan[SUP] 12 [/SUP], Xiaobing Chen[SUP] 13 [/SUP], Xiaomin Yan[SUP] 1 [/SUP], Zhaoping Zhang[SUP] 1 [/SUP], Jiacheng Liu[SUP] 14 [/SUP], Rui Huang[SUP] 1 [/SUP], Chuanwu Zhu[SUP] 2 [/SUP], Chao Wu[SUP] 1 [/SUP]
Affiliations
Abstract
in English, Spanish
Background: Few studies have investigated the impacts of metabolic syndrome (MS) on coronavirus disease 2019 (COVID-19). We described the clinical features and prognosis of confirmed COVID-19 patients with MS during hospitalization and after discharge.
Methods: Two hundred and thirty-three COVID-19 patients from the hospitals in 8 cities of Jiangsu, China were retrospectively included. Clinical characteristics of COVID-19 patients were described and risk factors of severe illness were analyzed by logistic regression analysis.
Results: Forty-five (19.3%) of 233 COVID-19 patients had MS. The median age of COVID-19 patients with MS was significantly higher than non-MS patients (53.0 years vs. 46.0 years, P = 0.004). There were no significant differences of clinical symptoms, abnormal chest CT images, and treatment drugs between two groups. More patients with MS had severe illness (33.3% vs. 6.4%, P < 0.001) and critical illness (4.4% vs. 0.5%, P = 0.037) than non-MS patients. The proportions of respiratory failure and acute respiratory distress syndrome in MS patients were also higher than non-MS patients during hospitalization. Multivariate analysis showed that concurrent MS (odds ratio [OR] 7.668, 95% confidence interval [CI] 3.062-19.201, P < 0.001) and lymphopenia (OR 3.315, 95% CI 1.306-8.411, P = 0.012) were independent risk factors of severe illness of COVID-19. At a median follow-up of 28 days after discharge, bilateral pneumonia was found in 95.2% of MS patients, while only 54.7% of non-MS patients presented bilateral pneumonia.
Conclusions: 19.3% of COVID-19 patients had MS in our study. COVID-19 patients with MS are more likely to develop severe complications and have worse prognosis. More attention should be paid to COVID-19 patients with MS.
Keywords: ARDS, acute respiratory distress syndrome; BMI, body mass index; COVID-19, coronavirus disease 2019; Coronavirus disease 2019; FBG, fasting blood glucose; ICU, intensive care units; IQR, interquartile range; MS, metabolic syndrome; Metabolic syndrome; Prognosis; SARS, severe acute respiratory syndrome; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TC, total cholesterol; TG, triglycerides; WHO, world Health Organization.
. 2022 May 27;158(10):458-465.
doi: 10.1016/j.medcle.2021.05.022. Epub 2022 Jun 9.
Clinical features and prognosis of COVID-19 patients with metabolic syndrome: A multicenter, retrospective study
Jian Wang[SUP] 1 [/SUP], Li Zhu[SUP] 2 [/SUP], Longgen Liu[SUP] 3 [/SUP], Xuebing Yan[SUP] 4 [/SUP], Leyang Xue[SUP] 5 [/SUP], Songping Huang[SUP] 6 [/SUP], Biao Zhang[SUP] 7 [/SUP], Tianmin Xu[SUP] 3 [/SUP], Fang Ji[SUP] 4 [/SUP], Chunyang Li[SUP] 4 [/SUP], Fang Ming[SUP] 6 [/SUP], Yun Zhao[SUP] 8 [/SUP], Juan Cheng[SUP] 9 [/SUP], Kang Chen[SUP] 10 [/SUP], Xiang-An Zhao[SUP] 11 [/SUP], Dawen Sang[SUP] 9 [/SUP], Xinying Guan[SUP] 12 [/SUP], Xiaobing Chen[SUP] 13 [/SUP], Xiaomin Yan[SUP] 1 [/SUP], Zhaoping Zhang[SUP] 1 [/SUP], Jiacheng Liu[SUP] 14 [/SUP], Rui Huang[SUP] 1 [/SUP], Chuanwu Zhu[SUP] 2 [/SUP], Chao Wu[SUP] 1 [/SUP]
Affiliations
- PMID: 35702719
- PMCID: PMC9181760
- DOI: 10.1016/j.medcle.2021.05.022
Abstract
in English, Spanish
Background: Few studies have investigated the impacts of metabolic syndrome (MS) on coronavirus disease 2019 (COVID-19). We described the clinical features and prognosis of confirmed COVID-19 patients with MS during hospitalization and after discharge.
Methods: Two hundred and thirty-three COVID-19 patients from the hospitals in 8 cities of Jiangsu, China were retrospectively included. Clinical characteristics of COVID-19 patients were described and risk factors of severe illness were analyzed by logistic regression analysis.
Results: Forty-five (19.3%) of 233 COVID-19 patients had MS. The median age of COVID-19 patients with MS was significantly higher than non-MS patients (53.0 years vs. 46.0 years, P = 0.004). There were no significant differences of clinical symptoms, abnormal chest CT images, and treatment drugs between two groups. More patients with MS had severe illness (33.3% vs. 6.4%, P < 0.001) and critical illness (4.4% vs. 0.5%, P = 0.037) than non-MS patients. The proportions of respiratory failure and acute respiratory distress syndrome in MS patients were also higher than non-MS patients during hospitalization. Multivariate analysis showed that concurrent MS (odds ratio [OR] 7.668, 95% confidence interval [CI] 3.062-19.201, P < 0.001) and lymphopenia (OR 3.315, 95% CI 1.306-8.411, P = 0.012) were independent risk factors of severe illness of COVID-19. At a median follow-up of 28 days after discharge, bilateral pneumonia was found in 95.2% of MS patients, while only 54.7% of non-MS patients presented bilateral pneumonia.
Conclusions: 19.3% of COVID-19 patients had MS in our study. COVID-19 patients with MS are more likely to develop severe complications and have worse prognosis. More attention should be paid to COVID-19 patients with MS.
Keywords: ARDS, acute respiratory distress syndrome; BMI, body mass index; COVID-19, coronavirus disease 2019; Coronavirus disease 2019; FBG, fasting blood glucose; ICU, intensive care units; IQR, interquartile range; MS, metabolic syndrome; Metabolic syndrome; Prognosis; SARS, severe acute respiratory syndrome; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TC, total cholesterol; TG, triglycerides; WHO, world Health Organization.